In primary care, second-line IBS therapy with amitriptyline vs. placebo reduced symptoms at 6 mo

Tanvi Gupta; Brooks D Cash

doi:10.7326/J23-0122

In primary care, second-line IBS therapy with amitriptyline vs. placebo reduced symptoms at 6 mo

Ann Intern Med. 2024 Feb;177(2):JC15. doi: 10.7326/J23-0122. Epub 2024 Feb 6.

Authors

Tanvi Gupta¹, Brooks D Cash¹

Affiliation

¹ University of Texas Health Science Center at Houston, Houston, Texas, USA (T.G., B.D.C.).

PMID: 38315998
DOI: 10.7326/J23-0122

Abstract

Ford AC, Wright-Hughes A, Alderson SL, et al; ATLANTIS trialists. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402:1773-1785. 37858323.

Publication types

Comment

MeSH terms

Amitriptyline / therapeutic use
Clinical Trials, Phase III as Topic
Double-Blind Method
Humans
Irritable Bowel Syndrome* / diagnosis
Irritable Bowel Syndrome* / drug therapy
Primary Health Care
Randomized Controlled Trials as Topic
Treatment Outcome

Substances

Amitriptyline